Indegene Limited (MAINBOARD)
May 6, 2024 - May 8, 2024
| Price | ₹430 - ₹452 |
| Premium | ₹275 |
|---|---|
| Lot size | 33 |
| Allotment | May 10, 2024 |
| Listing | May 13, 2024 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 33 | 14916 | 429231 |
| sHNI | 14 | 462 | 208824 | 4380 |
| bHNI | 68 | 2244 | 1014288 | 8760 |
Last Updated as on 08-May-2024 17:54:00
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 8094068 | 1559865945 | 192.72 |
| HNIs | 6070552 | 338981940 | 55.84 |
| HNIs (10L+) | 4047035 | 251864613 | 62.23 |
| HNIs (2-10L) | 2023517 | 87117327 | 43.05 |
| Retail | 14164620 | 110421729 | 7.8 |
| Employees | 296208 | 1949739 | 6.58 |
| Total | 28625448 | 2011219353 | 70.26 |
Application Wise Breakup (Approx) | |||
|---|---|---|---|
| Category | Reserved | Applied | Times |
| HNIs (10L+) | 8760 | 108020 | 12.33 |
| HNIs (2-10L) | 4380 | 178974 | 40.86 |
| Retail | 429231 | 2493188 | 5.81 |
| Total Application : 2780182 | |||
| © IPO Premium | |||
| QIB Interest Cost per share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹116.94 | @8% ₹133.65 | @9% ₹150.35 | @10% ₹167.06 | @11% ₹183.77 | @12% ₹200.47 |
| Big HNI (10L+) Cost per lot (7 Days) |
|---|
| Assuming fix interest of ₹2000 per application Big HNI (10L+) costing for every 1 lot allotment is ₹24892 |
Top 5 Anchor Investor
| Name of Anchor | No. of Shares | % Portion | Amount (cr) |
|---|---|---|---|
| SMALLCAP WORLD FUND, INC | 1106094 | 9.11% | 50.00 |
| FIDELITY FUNDS - INDIA FOCUS FUND | 929181 | 7.65% | 42.00 |
| ICICI PRUDENTIAL TECHNOLOGY FUND | 929181 | 7.65% | 42.00 |
| NIPPON LIFE INDIA TRUSTEE LTDA/C NIPPON INDIA SMALL CAP FUND | 929181 | 7.65% | 42.00 |
| CUSTODY BANK OF JAPAN, LTD. RE: RB AMUNDI INDIA SMALL CAP EQUITY MOTHER FUND | 884928 | 7.29% | 40.00 |
Established in 1998, Indegene Limited is a prominent provider of digital services tailored for the life sciences industry, offering comprehensive support ranging from drug development and clinical trials to regulatory submissions and sales/marketing assistance. The company's diverse portfolio is categorized into Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Enterprise Clinical Solutions, along with consultancy services. Additionally, its subsidiary, DT Associates Limited, operating under the "DT Consulting" brand, specializes in guiding life sciences firms through digital transformation endeavors for enhanced customer experiences. Noteworthy accolades include the Platinum Level award received at the 2023 Healthy Workplace Conference and Awards, underscoring its commitment to employee well-being and organizational excellence. With an extensive global presence, Indegene Limited serves 65 active clients and employs 5,181 professionals worldwide, with a significant workforce based in India, North America, Europe, China, and other regions, highlighting its capacity to deliver innovative solutions and support to the life sciences sector.
IPO Details
| Issue Size | Up to [40,746,891]Equity Shares aggregating up to[1841.76] Cr |
| Fresh Issue | Up to [16,814,159] Equity Shares aggregating up to 760 Cr |
| Offer For Sale | Up to [23,932,732] Equity Shares aggregating up to[1081.76] Cr |
| Listing At | BSE,NSE |
| Share holding pre issue | 222,435,091 Equity Shares |
| Share holding post issue | 239,249,250 Equity Shares |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the net issue. |
| NII Shares Offered | Not less than 15% of the net issue. |
| Retail Shares Offered | Not less than 35% of the net issue. |
Key Performance Indicators
| KPI | Dec-23 | Mar-23 | Mar-22 |
|---|---|---|---|
| RONW | 18.23% | 25.02% | 21.57% |
| EPS (basic & Diluted) |
10.84 | 11.97 | 7.46 |
| P/BV | 7.55 | ||
|
P/E Pre IPO |
37.78 |
Financial Information (Restated Consolidated)
| Period | Dec-23 | Mar-23 | Mar-22 | Mar-21 |
|---|---|---|---|---|
| Assets | 2518.15 | 2203.87 | 1353.47 | 596.04 |
| Revenue | 1969.75 | 2364.10 | 1690.50 | 996.92 |
| Profit After Tax | 241.90 | 266.10 | 162.82 | 185.68 |
| Net Worth | 1327.00 | 1063.72 | 763.90 | 324.51 |
| Reserve & Surplus | 1282.65 | 1019.43 | 763.55 | 324.19 |
| Total Borrowing | 399.33 | 394.34 | 18.24 | 24.76 |
| Amount in Crores | ||||
Strength Factors
Domain Expertise in Healthcare: With a significant portion of its workforce possessing healthcare-related educational backgrounds, the company demonstrates a deep understanding of the healthcare domain. This expertise enables the company to offer tailored solutions and insights to its clients, addressing complex challenges in the industry effectively.
Robust Digital Capabilities and Proprietary Technology Portfolio: The Company boasts a suite of proprietary tools and platforms, leveraging advanced technologies such as artificial intelligence, machine learning, natural language processing, generative artificial intelligence, and advanced analytics. These digital capabilities empower the company to automate processes, enhance operational efficiencies, and deliver innovative solutions that drive value for its clients.
Track Record of Establishing Long-Standing Client Relationships: Through its commitment to excellence and delivery of high-quality services, the company has established enduring partnerships with marquee biopharmaceutical companies, including the 20 largest biopharmaceutical companies globally by revenue. This track record underscores the company's reliability, trustworthiness, and ability to consistently meet the evolving needs of its clients, fostering enduring relationships built on mutual success and collaboration.
Risk Factors
Vulnerability to Industry Trends: As a player in the life sciences industry, the company is subject to the dynamics and fluctuations of this sector, including factors like regulatory changes, shifts in healthcare policies, and technological advancements. Adverse trends in the life sciences industry, such as slower growth rates or increased competition, could negatively impact the company's revenue and profitability.
Complex Revenue Models: The complexity and unfamiliarity of the company's business and revenue models may present challenges in attracting and retaining investors. Prospective investors may hesitate due to a lack of understanding or uncertainty about the company's financial prospects, potentially limiting access to capital and hindering the company's growth initiatives.
Link Intime India Private Limited
Tel: +91 810 811 4949
E-mail: indegene.ipo@linkintime.co.in
Website: www.linkintime.co.in